1. Home
  2. SLNO vs PAY Comparison

SLNO vs PAY Comparison

Compare SLNO & PAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLNO
  • PAY
  • Stock Information
  • Founded
  • SLNO 1999
  • PAY 2004
  • Country
  • SLNO United States
  • PAY United States
  • Employees
  • SLNO N/A
  • PAY N/A
  • Industry
  • SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • PAY Computer Software: Prepackaged Software
  • Sector
  • SLNO Health Care
  • PAY Technology
  • Exchange
  • SLNO Nasdaq
  • PAY Nasdaq
  • Market Cap
  • SLNO 3.8B
  • PAY 4.4B
  • IPO Year
  • SLNO 2014
  • PAY 2021
  • Fundamental
  • Price
  • SLNO $49.71
  • PAY $33.09
  • Analyst Decision
  • SLNO Strong Buy
  • PAY Buy
  • Analyst Count
  • SLNO 10
  • PAY 7
  • Target Price
  • SLNO $112.50
  • PAY $36.50
  • AVG Volume (30 Days)
  • SLNO 1.7M
  • PAY 836.2K
  • Earning Date
  • SLNO 11-05-2025
  • PAY 11-11-2025
  • Dividend Yield
  • SLNO N/A
  • PAY N/A
  • EPS Growth
  • SLNO N/A
  • PAY 69.57
  • EPS
  • SLNO N/A
  • PAY 0.44
  • Revenue
  • SLNO $32,656,999.00
  • PAY $1,044,760,000.00
  • Revenue This Year
  • SLNO N/A
  • PAY $31.46
  • Revenue Next Year
  • SLNO $175.39
  • PAY $20.33
  • P/E Ratio
  • SLNO N/A
  • PAY $75.01
  • Revenue Growth
  • SLNO N/A
  • PAY 49.35
  • 52 Week Low
  • SLNO $41.50
  • PAY $19.53
  • 52 Week High
  • SLNO $90.32
  • PAY $40.43
  • Technical
  • Relative Strength Index (RSI)
  • SLNO 22.26
  • PAY 38.80
  • Support Level
  • SLNO $50.63
  • PAY $31.84
  • Resistance Level
  • SLNO $72.99
  • PAY $35.97
  • Average True Range (ATR)
  • SLNO 4.32
  • PAY 1.23
  • MACD
  • SLNO -1.60
  • PAY -0.81
  • Stochastic Oscillator
  • SLNO 3.34
  • PAY 16.58

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

About PAY Paymentus Holdings Inc.

Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers and financial institutions through a Software-as-a-Service, (SaaS), secure, omni-channel technology platform. The platform integrates into a biller's core financial and operating systems to provide flexible and secure access to payment processing of credit cards, debit cards, eChecks and digital wallets across a number of channels including online, mobile, IVR, call center, chatbot and voice-based assistants. The Company generates revenue from payment transaction fees processed through the Company's platform. The fees are generated as a percentage of transaction value or a specified fee per transaction.

Share on Social Networks: